FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to urology and andrology, and can be used for treating autoimmune male sterility. The method involves intramuscular injections of Longidase 3000 IU twice a week for 3 months.
EFFECT: use of the invention enables normalising ejaculate viscosity, increasing a number of A and B sperm cells, decreasing a number of pathological sperm cells, eliminating agglutination and agglomeration of sperm cells, normalising pH value ensured by lower concentration of antisperm antibodies on a sperm cell surface and in a sperm fluid.
2 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD OF TREATING OBSTRUCTIVE AZOOSPERMIA AND CRYPTOZOOSPERMIA IN PATIENTS WITH CHRONIC PROSTATITIS | 2015 |
|
RU2586305C1 |
METHOD FOR APPLYING CRYOPLSMASORPTION | 2003 |
|
RU2238110C1 |
METHOD FOR PREDICTION OF EFFICIENCY OF LOW-INTENSITY LASER THERAPY IN AUTOIMMUNE INFERTILITY IN MEN | 2020 |
|
RU2752994C1 |
METHOD FOR PREDICTION OF MALE REPRODUCTIVE FUNCTION NORMALISATION FOLLOWING VARICOCELECTOMY | 2012 |
|
RU2519185C1 |
METHOD FOR TREATING AUTOIMMUNE MALE INFERTILITY CASES | 2005 |
|
RU2294779C1 |
METHOD OF TREATING MALE STERILITY CAUSED BY AUTOIMMUNE RESPONSE TO SPERM CELLS | 2012 |
|
RU2517061C1 |
METHOD OF PHARMACOLOGICAL TREATMENT OF AUTOIMMUNE MALE STERILITY | 1998 |
|
RU2149021C1 |
METHOD FOR TREATING AUTOIMMUNE MALE INFERTILITY | 1998 |
|
RU2155596C2 |
METHOD FOR IDENTIFICATION OF RISK GROUPS AMONG PATIENTS FOR THE DEVELOPMENT OF TERATOZOSPERMIA | 2020 |
|
RU2741499C1 |
METHOD FOR DETERMINING RISK OF OLIGOZOOSPERMIA IN MEN WITH NORMOZOOSPERMIA | 2020 |
|
RU2736002C1 |
Authors
Dates
2011-10-10—Published
2010-04-13—Filed